Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ITRM vs OVID: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–1 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: ITRM 2 – 3 OVID (1 Tie) Matrix Metrics: ITRM 1 – 8 OVID

As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin).

  • Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ITRM vs OVID
ITRM NASDAQ
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap $3.8M
TTM Revenue $390,000
Forward P/E N/M
Beta / 30D Vol 1.61β · 508% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.15 · SMA50: $0.23
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.20
-5.98% 1D
Market Cap $424.6M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 1.04β · 97% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $2.49 · SMA50: $2.46

6-Pillar Scorecard Institutional Category Breakdown (ITRM 2 – 3 OVID)

Columns: Metric · ITRM · OVID
1. Valuation Multiples OVID
Forward P/E N/M 1.8x
Trailing P/E N/M 1.8x
PEG Ratio N/M N/M
EV / Revenue 9.6x N/M
2. Growth & Scale OVID
Revenue Growth (YoY) -100.0% -88.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $390,000 $1.5M
Market Cap $3.8M $424.6M
3. Profitability & Quality OVID
Gross Margin 29.7% 100.0%
Operating Margin -1982.3% -4693.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -555.7% -35.4%
4. Balance Sheet & Cash Flow ITRM
Cash Generation (TTM) -$19M EBITDA -$58M
Cash Flow Margin N/A N/A
Net Cash / Leverage -555.7% ROE $1.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ITRM
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 11.7% (<1st %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ITRM (1) vs OVID (8)
Institutional Metric ITRM OVID Criterion Row Edge
Market Capitalization
Scale
$3.8M $424.6M Larger Scale OVID
Trailing P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Forward P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Revenue Growth (YoY)
Growth
-100.0% -88.3% Higher Growth OVID
Operating Margin (TTM)
Profitability
-1982.3% -4693.7% Higher Margin ITRM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-555.7% -35.4% Higher ROE OVID
52-Week Range Position
Momentum
0% ($0–$1) 52% ($1–$3) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
1.61β · 508% Vol 1.04β · 97% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
50.5 / 100 (HOLD) 52.3 / 100 (HOLD) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
$390,000 $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.7% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M EBITDA (-555.7% ROE) -$58M ($1.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OVID +123.11 pp
ITRM: -89.38% · OVID: +33.73%
3M Horizon OVID +124.17 pp
ITRM: -89.62% · OVID: +34.55%
6M Horizon OVID +165.65 pp
ITRM: -92.21% · OVID: +73.44%
1Y Horizon OVID +165.65 pp
ITRM: -92.21% · OVID: +73.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITRM vs OVID. Trailing 12-month operating profitability (ITRM -1982.3% vs OVID -4693.7%) and valuation multiples (ITRM N/M vs OVID 1.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ITRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$390,000
Gross Margin29.7%
Op. Margin-1982.3%
ROE / Fwd P/E-555.7% · N/M
OVID ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross Margin100.0%
Op. Margin-4693.7%
ROE / Fwd P/E-35.4% · 1.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ITRM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OVID BREAKDOWN
154d in phase · OBV DISTRIBUTION
Current IV 11.7%
IV Percentile <1st %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ITRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -1982.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $424.6M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ITRM vs OVID Key Questions & Quantitative Answers

As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin). Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OVID leads the Growth & Scale pillar: ITRM posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). On trailing 12-month operating scale, ITRM generates $390,000 in USD-normalized revenue versus $1.5M for OVID. In operating R&D and SG&A reinvestment, ITRM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.

OVID screens cheaper on headline valuation multiples. ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITRM (-555.7% ROE) versus OVID (-35.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk). By comparison, OVID carries 11.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.04β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.